Inotek Pharmaceuticals Corp (ITEK) : New Leaf Venture Partners L.l.c. added new position in Inotek Pharmaceuticals Corp during the most recent quarter end. The investment management firm now holds 50,300 shares of Inotek Pharmaceuticals Corp which is valued at $352,100 , the company said in a statement filed on Nov 14, 2016 with the SEC.Inotek Pharmaceuticals Corp makes up approximately 0.25% of New Leaf Venture Partners L.l.c.’s portfolio.
Other Hedge Funds, Including , D. E. Shaw boosted its stake in ITEK in the latest quarter, The investment management firm added 109,902 additional shares and now holds a total of 142,747 shares of Inotek Pharmaceuticals Corp which is valued at $1,006,366.Geode Capital Management boosted its stake in ITEK in the latest quarter, The investment management firm added 21,661 additional shares and now holds a total of 124,962 shares of Inotek Pharmaceuticals Corp which is valued at $874,734.Ft Options boosted its stake in ITEK in the latest quarter, The investment management firm added 12,113 additional shares and now holds a total of 156,864 shares of Inotek Pharmaceuticals Corp which is valued at $1,098,048. Inotek Pharmaceuticals Corp makes up approx 1.38% of Ft Options’s portfolio.Blackrock Investment Management reduced its stake in ITEK by selling 431 shares or 0.41% in the most recent quarter. The Hedge Fund company now holds 104,508 shares of ITEK which is valued at $689,753.
Inotek Pharmaceuticals Corp closed down -0.05 points or -0.77% at $6.45 with 8,00,425 shares getting traded on Monday. Post opening the session at $6.6, the shares hit an intraday low of $6.25 and an intraday high of $6.6 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Inotek Pharmaceuticals Corp. H.C. Wainwright Initiated Inotek Pharmaceuticals Corp on Sep 20, 2016 to “Buy”, Price Target of the shares are set at $22.
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Company’s business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery development and commercialization of therapies for glaucoma. Its lead product candidate trabodenoson is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company’s product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).